Overview

  • Product nameAnti-Apolipoprotein A V antibody
    See all Apolipoprotein A V primary antibodies
  • Description
    Goat polyclonal to Apolipoprotein A V
  • Tested applicationsSuitable for: ELISA, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Baboon
  • Immunogen

    Synthetic peptide:

    HSLHDQGHSHLGDP

    (human) from the C terminus of the Apolipoprotein A V protein sequence according to NP_443200.2.

  • Positive control
    • Human liver lysates

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab77358 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA
WB
  • Application notesPeptide ELISA: Antibody detection limit dilution 1/64000.
    WB: Use at a concentration of 0.3 - 1 µg/ml. Predicted molecular weight: 41 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionMinor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages.
    • Tissue specificityLiver and plasma.
    • Involvement in diseaseDefects in APOA5 are a cause of susceptibility to familial hypertriglyceridemia (FHTR)[MIM:145750].mFamilial hypertriglyceridemia is a common inherited disorder in which the concentration of very low density lipoprotein (VLDL) is elevated in the plasma. This leads to increased risk of heart disease, obesity, and pancreatitis.
      Defects in APOA5 are a cause of hyperlipoproteinemia type 5 (HLPP5) [MIM:144650]. HLPP5 is characterized by increased amounts of chylomicrons and very low density lipoprotein (VLDL) and decreased low density lipoprotein (LDL) and high density lipoprotein (HDL) in the plasma after a fast. Numerous conditions cause this phenotype, including insulin-dependent diabetes mellitus, contraceptive steroids, alcohol abuse, and glycogen storage disease type 1A (GSD1A) [MIM:232200].
    • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
    • Post-translational
      modifications
      Phosphorylation sites are present in the extracelllular medium.
    • Cellular localizationSecreted.
    • Information by UniProt
    • Database links
    • Alternative names
      • Apo-AV antibody
      • ApoA-V antibody
      • Apoa5 antibody
      • APOA5_HUMAN antibody
      • ApoAV antibody
      • Apolipoprotein A-V antibody
      • Apolipoprotein A5 antibody
      • RAP3 antibody
      • Regeneration associated protein 3 antibody
      • Regeneration-associated protein 3 antibody
      see all

    Anti-Apolipoprotein A V antibody images

    References for Anti-Apolipoprotein A V antibody (ab77358)

    ab77358 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab77358.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"